LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.

SITOGLUSIDE (Daucosterol) inhibits cancer cell proliferation by inducing autophagy through reactive oxygen species-dependent manner. It also perturbs cell cycle and induces apoptotic cell death in A549 cells. Daucosterol has being shown to promote the proliferation of neural stem cells. Daucosterol also protects neurons against oxygen-glucose deprivation/reperfusion-mediated injury by activating IGF1 signaling pathway. Daucosterol could be potentially developed as a medicine for ischemic stroke treatment.

Tifluadom is an opioid benzodiazepine with potent analgesic activity. Studies using antagonists for κ-, δ-, and μ-opiate receptors in guinea pig myenteric plexus-longitudinal muscle preparation and mouse and rabbit vasa deferentia showed that Tifluadom is an opioid analgesic with a preference for opiate κ-receptors. In rat brain homogenates, tifluadom displaced kappa-antagonist naloxone from its binding sites with an IC50 of 12nM but had no effect on flunitrazepam binding. Tifluadom produced a dose-related diuresis in normally hydrated rats and the diuretic effect was antagonized by naloxone and blocked by morphine administration.

Indopine is indolylalkyl derivative patented by Irwin, Neisler and Co as potent analgesic.

Benafentrine (also known as AH 21-132), an inhibitor of the phosphodiesterase (PDE) III and IV isoenzymes, had an anti-allergic effect and was studied for the treatment of allergic bronchial asthma. However, the development of the drug was discontinued at phase I.

Tiopropamine is an anti-inflammatory agent. Tiopropamine hydrochloride has been used in the treatment of peptic ulcers.

Tiflorex (also known as (+)-Flutiorex) is a phenylalkylamine derivative patented by Synthelabo S. A. as an anorectic agent. Tiflorex acts as a central nervous system stimulant form amphetamine class with little effect on pulse rate, sleep, or mood. In preclinical models, Tiflorex provoked a dose-dependent reduction in the consumption of the protein-rich diet and a reduction in the consumption of the protein-poor diet.

Protheobromine is a derivative of the xanthine alkaloid theobromine with diuretic and vasodilating activity.